Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Payables (2022 - 2025)

Historic Payables for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $5.4 million.

  • Taysha Gene Therapies' Payables rose 1025.95% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 1025.95%. This contributed to the annual value of $3.6 million for FY2024, which is 4357.52% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Payables stood at $5.4 million for Q3 2025, which was up 1025.95% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Payables registered a high of $24.0 million during Q2 2022, and its lowest value of $3.6 million during Q4 2024.
  • For the 4-year period, Taysha Gene Therapies' Payables averaged around $10.1 million, with its median value being $8.7 million (2024).
  • Its Payables has fluctuated over the past 5 years, first plummeted by 5907.62% in 2023, then skyrocketed by 1530.77% in 2024.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Payables stood at $10.9 million in 2022, then crashed by 41.84% to $6.4 million in 2023, then tumbled by 43.58% to $3.6 million in 2024, then skyrocketed by 51.39% to $5.4 million in 2025.
  • Its Payables stands at $5.4 million for Q3 2025, versus $7.7 million for Q2 2025 and $4.3 million for Q1 2025.